---
schema_version: "secwatch.filing_event.v1"
accession: "0001380106-23-000072"
form_type: "8-K"
ticker: "RPID"
cik: "0001380106"
company_name: "RAPID MICRO BIOSYSTEMS, INC."
filed_at: "2023-05-05T23:59:59+00:00"
generated_at: "2026-06-15T16:16:04.027002+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Rapid Micro Biosystems Q1 revenue $5.0M (+21% YoY); reaffirms FY23 guidance of at least $22.0M

## Summary
- Total revenue $5.0M, up 21% YoY; recurring revenue $3.3M (+22%).
- Net loss $13.9M ($0.32/share) vs $14.9M ($0.35) in Q1 2022.
- Placed three Growth Direct systems; two systems validated in the quarter.
- Reaffirmed FY2023 revenue guidance of at least $22.0M (~30% growth) and at least 15 placements.
- Appointed Michael Wysocki SVP Sales and Marketing; cash $122.1M, no debt.

## SEC filing metadata
- accession: 0001380106-23-000072
- form_type: 8-K
- ticker: RPID
- cik: 0001380106
- company_name: RAPID MICRO BIOSYSTEMS, INC.
- filed_at: 2023-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1380106/000138010623000072/0001380106-23-000072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1380106/000138010623000072/rpid-20230505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001380106-23-000072
- JSON: https://secwatch.observer/filing/0001380106-23-000072.json
- Plain text: https://secwatch.observer/filing/0001380106-23-000072.txt

## Key facts
- Earnings Releases
  RAPID MICRO BIOSYSTEMS, INC. reported first quarter ended March 31, 2023 results: revenue $5.0 million, net income $13.9 million, EPS $0.32. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2023
  - Revenue: $5.0 million
  - Net income: $13.9 million
  - EPS: $0.32
  - Guidance: reaffirmed
  - Result: reported results
  source text: expressly stated in such filing. --- EX-99.1 (EX-99.1) --- Rapid Micro Biosystems Reports First Quarter 2023 Financial Results Reports first quarter 2023 total revenue of $5.0 million, representing growth of 21%, compared to first quarter 2022 Reaffirms full year 2023 total revenue guidance of at least $22.0 million, representing growth of approximately 30%,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1380106/000138010623000072/0001380106-23-000072-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.